See more : Swedish Orphan Biovitrum AB (publ) (BIOVF) Income Statement Analysis – Financial Results
Complete financial analysis of 4D pharma plc (DDDD.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 4D pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Fun Yours Technology Co.,Ltd. (6482.TWO) Income Statement Analysis – Financial Results
- Fiesta Restaurant Group, Inc. (FRGI) Income Statement Analysis – Financial Results
- Globetronics Technology Bhd. (7022.KL) Income Statement Analysis – Financial Results
- Deutsche Rohstoff AG (DR0.DE) Income Statement Analysis – Financial Results
- Kernel Group Holdings, Inc. (KRNLW) Income Statement Analysis – Financial Results
4D pharma plc (DDDD.L)
About 4D pharma plc
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 718.00K | 534.00K | 211.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 718.00K | 534.00K | 211.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.63M | 22.04M | 26.51M | 24.91M | 16.91M | 10.22M | 6.90M | 1.82M |
| General & Administrative | 15.89M | 4.10M | 1.57M | 2.24M | 2.13M | 1.93M | 2.24M | 868.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.89M | 4.10M | 1.57M | 2.24M | 2.13M | 1.93M | 2.24M | 868.00K |
| Other Expenses | 0.00 | 4.94M | 2.74M | 1.97M | 1.32M | 940.00K | 1.46M | 782.00K |
| Operating Expenses | 37.52M | 31.08M | 30.83M | 29.12M | 20.36M | 13.09M | 10.59M | 3.47M |
| Cost & Expenses | 37.52M | 31.08M | 30.83M | 29.12M | 20.36M | 13.09M | 10.59M | 3.47M |
| Interest Income | 1.00K | 5.00K | 61.00K | 282.00K | 482.00K | 652.00K | 451.00K | 92.00K |
| Interest Expense | 581.00K | 173.00K | 514.00K | 348.00K | 123.00K | 71.00K | 0.00 | 5.00K |
| Depreciation & Amortization | 1.35M | 1.21M | 1.28M | 1.20M | 982.00K | 618.00K | 253.00K | 114.00K |
| EBITDA | -30.03M | -28.97M | -27.63M | -26.89M | -22.88M | -11.02M | -9.62M | -1.90M |
| EBITDA Ratio | -4,181.89% | -5,424.53% | -13,095.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.38M | -30.17M | -28.91M | -28.09M | -23.86M | -11.64M | -9.88M | -2.02M |
| Operating Income Ratio | -4,370.33% | -5,650.37% | -13,702.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -581.00K | -173.00K | -514.00K | -348.00K | -123.00K | -71.00K | -184.00K | -364.00K |
| Income Before Tax | -31.96M | -30.35M | -29.43M | -28.44M | -23.99M | -11.71M | -10.06M | -2.38M |
| Income Before Tax Ratio | -4,451.25% | -5,682.77% | -13,945.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -22.00K | -4.38M | -5.36M | -4.75M | -3.54M | -1.84M | -2.33M | 5.00K |
| Net Income | -31.94M | -25.96M | -24.07M | -23.69M | -20.45M | -9.86M | -7.73M | -2.39M |
| Net Income Ratio | -4,448.19% | -4,861.99% | -11,405.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.23 | -0.37 | -0.36 | -0.31 | -0.15 | -0.13 | -0.06 |
| EPS Diluted | -0.30 | -0.23 | -0.37 | -0.36 | -0.31 | -0.15 | -0.13 | -0.06 |
| Weighted Avg Shares Out | 107.49M | 113.85M | 65.49M | 65.49M | 65.08M | 64.86M | 59.82M | 42.00M |
| Weighted Avg Shares Out (Dil) | 107.49M | 113.85M | 65.49M | 65.49M | 65.08M | 64.86M | 59.82M | 42.00M |
Source: https://incomestatements.info
Category: Stock Reports